A new report from a relatively small, single-institution study has provided additional information about the utility of [18F]fluciclovine (Axumin) PET/CT scans in the detection of recurrent prostate cancer after definitive first-line treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Axumin, fluciclovine, PET/CT, recurrence, scan | 2 Comments »
We had previously reported on a presentation by Calais et al. earlier this year. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, fluorine-18, gallium-68, imaging, PET/CT, PSMA, scan | 9 Comments »
A small, Norwegian, Phase II clinical trial has explored the potential diagnostic value of [18F]fluciclovine PET/MRI scans of the pelvic lymph nodes in staging for patients with high-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Axumin, detection, lymph node, positive, risk, scan | 1 Comment »
The value of many cancer-related tests is actually based on whether the results of the particular test change the way that physicians plan to treat specific patients (hopefully for the better). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Axumin, fluciclovine, PET, recurrence, scan, Treatment | Leave a comment »
Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …
Filed under: Living with Prostate Cancer, Uncategorized | Tagged: Axumin, imaging, PET, scan, [18F]fluciclovine | 4 Comments »
Back in May this year we reported that the US Food and Drug Administration had approved a new type of imaging agent known as [18F]fluciclovine (Axumin®) for use in association with PET scans in men with recurrent prostate cancer that might have spread to other parts of the body, but which was not evident on older forms of scan. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, PET, scan | Leave a comment »
Last Friday the US Food and Drug Administration (FDA) last Friday approved a new type of imaging agent for use in PET/CT scans for men with suspected prostate cancer recurrence after earlier treatment. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, imaging, recurrence | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 